Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Inclusion Criteria: 1. Adult patient with chronic or persistent ITP. 2. Must have failed or are unable to receive standard of care treatments for ITP. 3. Must have at least two platelet counts \< 30,000/µL during the last 2 months prior to screen date. Exclusion Criteria: 1. ITP associated with lymphoma, chronic lymphocytic leukemia, transplant, or thrombocytopenia associated with myeloid dysplasia. 2. Subject has uncontrolled or poorly controlled hypertension. 3. Any of the following laboratory abnormalities: neutrophil count of \< 1,500/µL, or transaminase levels (ALT, AST) \> 1.5x ULN, total bilirubin \> 2.0 mg/dL. 4. Active HBV or HCV infection. 5. Current or recent enrollment in an investigational drug or device study.